Lantheus Holdings (LNTH) Change in Receivables (2014 - 2026)
Lantheus Holdings' (LNTH) quarterly Change in Receivables came in at $2.2 million in Q1 2026, down 91.53% year-on-year from $26.4 million in Q1 2025, and up 7.98% on a QoQ basis from $2.1 million in Q4 2025.
Lantheus Holdings (LNTH) Change in Receivables (2014 - 2026) Analysis & Trends
Lantheus Holdings (LNTH) has 13 years of Change in Receivables data on file, last reported at $2.2 million in Q1 2026.
- On a quarterly basis, Change in Receivables fell 91.53% year-over-year to $2.2 million in Q1 2026; TTM through Mar 2026 was -$6.2 million, a 172.53% decrease from a year earlier, with the FY2025 full-year figure at $17.9 million, down 52.53% from the prior year.
- Change in Receivables for Q1 2026 stood at $2.2 million, up from $2.1 million in the prior quarter.
- Over the last five years, Change in Receivables for LNTH reached as high as $85.2 million in Q1 2022 and fell as low as -$43.1 million in Q3 2024.
- Historically, Change in Receivables has averaged $15.0 million across 5 years, with a median of $14.4 million in 2023.
- Across the five-year window, Change in Receivables jumped 3529.8% in 2022 and sank 1187.77% in 2024, its largest moves.
- Year by year, Change in Receivables stood at $16.4 million in 2022, then surged by 55.78% to $25.6 million in 2023, then slumped by 128.14% to -$7.2 million in 2024, then jumped by 128.7% to $2.1 million in 2025, then climbed by 7.98% to $2.2 million in 2026.
- Per Business Quant data, the three most recent Change in Receivables figures were $2.2 million in Q1 2026, $2.1 million in Q4 2025, and -$12.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -78.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 106.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -621.82 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -38.20 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 126.30 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 81.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Lantheus Holdings | 6.72 Bn | 6.22 Bn | 230.92 Mn | 2.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.23 Mn |
| Mar 31, 2026 | 2.23 Mn |
| Dec 31, 2025 | 2.07 Mn |
| Dec 31, 2025 | 2.07 Mn |
| Sep 30, 2025 | -12.83 Mn |
| Sep 30, 2025 | -12.83 Mn |
| Jun 30, 2025 | 2.29 Mn |
| Jun 30, 2025 | 2.29 Mn |
| Mar 31, 2025 | 26.36 Mn |
| Mar 31, 2025 | 26.36 Mn |
| Dec 31, 2024 | -7.20 Mn |
| Dec 31, 2024 | -7.20 Mn |
| Sep 30, 2024 | -43.14 Mn |
| Sep 30, 2024 | -43.14 Mn |
| Jun 30, 2024 | 32.59 Mn |
| Jun 30, 2024 | 32.59 Mn |
| Mar 31, 2024 | 55.44 Mn |
| Mar 31, 2024 | 55.44 Mn |
| Dec 31, 2023 | 25.59 Mn |
| Dec 31, 2023 | 25.59 Mn |